<DOC>
	<DOCNO>NCT01851551</DOCNO>
	<brief_summary>This Phase 1/2 study perform two clinical center US UK . It single arm , open label study evaluate VSLI plus rituximab adult aggressive relapse refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Phase 1/2 Study VSLI Plus Rituximab Patients With Relapsed and/or Refractory NHL</brief_title>
	<detailed_description>The primary efficacy endpoint objective response rate , define proportion patient response CR + PR . Duration response , time progression , overall survival analyze . Descriptive statistic use demographic , disease characteristic , treatment exposure , efficacy , safety variable .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologicallyconfirmed diffuse large Bcell nonHodgkin 's lymphoma ( NHL ) , define Revised European American Lymphoma/WHO classification . This include : diffuse large Bcell , primary mediastinal large Bcell lymphoma sclerosis , intravascular large Bcell lymphoma , immunoblastic Bcell lymphoma , Tcell rich Bcell lymphoma anaplastic large Bcell lymphoma . In US protocol , patient transformation indolent lymphoma mantle cell lymphoma eligible . Confirmation CD20 expression lymphoma cell . Eastern Cooperative Oncology Group ( ECOG ) ≤2 . One prior chemotherapy regimen . Patients receive prior rituximab therapy part induction chemotherapy regimen previous response rituximab single agent eligible . Measurable disease least 1 site , previously irradiate . Measurable disease define least 1 bidimensionally measurable lesion clearly define margin ≥1.5 cm large dimension determine physical examination compute tomography ( CT ) scan . Total bilirubin serum creatinine ≤2 time ULN . Absolute neutrophil count ( ANC ) ≥0.5 × 109/L , platelet ≥50 × 109/L . 18 year age old . Women childbearing potential willing use acceptable method contraception throughout course study . Signed date informed consent form . Known transformation indolent lymphoma ( UK protocol ) . Eligible conventional highdose chemotherapy curative intent . Radiotherapy , chemotherapy , immunotherapy , corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within past 4 week . Any previous malignancy less 5year complete remission interval , except curatively resect basal cell carcinoma curatively resect situ carcinoma uterine cervix . History active CNSlymphoma , AIDSrelated lymphoma , uncontrolled severe medical illness infection . History neurologic disorder unrelated chemotherapy ( include familial neurologic disease acquire demyelinate disorder ) . Grade 3 4 sensory motor neuropathy screening relate prior chemotherapy . Major surgery ( exclude diagnosis ) within 4 week enrollment . Pregnant lactate woman ( woman childbearing potential underwent pregnancy test ) . Allergy vincristine , vinca alkaloid . Progressive disease receive within 1 month receive previous rituximab therapy ( US protocol ) . Hypersensitivity component rituximab murine protein ( UK protocol ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>NHL</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>diffuse large b-cell lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
</DOC>